Literature DB >> 27291066

Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.

S R Lentz1, M Cerqueira2, D Janic3, C Kempton4, I Matytsina5, M Misgav6, J Oldenburg7, M Ozelo8, M Recht9, A Rosholm5, A Savic10, T Suzuki11, A Tiede12, E Santagostino13.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27291066     DOI： 10.1111/hae.12990

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  3 in total

1.  Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.

Authors:  Masahiro Takeyama; Keiji Nogami; Ryohei Kobayashi; Kenichi Ogiwara; Akira Taniguchi; Yasuaki Nakanishi; Yusuke Inagaki; Yasuhito Tanaka; Midori Shima
Journal:  Int J Hematol       Date:  2018-01-30       Impact factor: 2.490

Review 2.  Current and emerging factor VIII replacement products for hemophilia A.

Authors:  Lorraine A Cafuir; Christine L Kempton
Journal:  Ther Adv Hematol       Date:  2017-08-26

Review 3.  Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

Authors:  Maria Elisa Mancuso; Elena Santagostino
Journal:  J Clin Med       Date:  2017-03-28       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.